Rasdegafusp alfa

DB15185InvestigationalVaccines

Rasdegafusp alfa is under investigation in clinical trial NCT03206047 (Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer).

Mechanism: Pharmacologically active on Cancer/testis antigen 1 and Lymphocyte antigen 75
Curator reviewed
Code names: CDX-1401

Resolves to

Compound

UNIISU9AMV39DBCAS1587257-96-2

Targets

P78358CTAG1AO60449LY75

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rasdegafusp alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account